Palatability evaluation of orally disintegrating tablets using a visual analog scale in clinical trials
CONCLUSION: The VAS method for assessing ODT palatability provides accurate information and can contribute to the design and manufacture of patient-friendly pharmaceutical products.PMID:38699974 | DOI:10.5414/CP204477 (Source: Clinical Pharmacology and Therapeutics)
Source: Clinical Pharmacology and Therapeutics - May 3, 2024 Category: Drugs & Pharmacology Authors: Motoyasu Miura Seiki Kojima Shimako Tanaka Yasuharu Kashiwagura Noriyuki Namiki Shinya Uchida Source Type: research
The Role of OX40-OX40L Axis in the Pathogenesis of Atopic Dermatitis
Dermatitis. 2024 May 3. doi: 10.1089/derm.2024.0058. Online ahead of print.ABSTRACT OX40 is a co-stimulatory immune checkpoint molecule that promotes the activation and the effector function of T lymphocytes through interaction with its ligand (OX40L) on antigen-presenting cells. OX40-OX40L axis plays a crucial role in Th1 and Th2 cell expansion, particularly during the late phases or long-lasting response. Atopic dermatitis is characterized by an immune dysregulation of Th2 activity and by an overproduction of proinflammatory cytokines such as interleukin (IL)-4 and IL-13. Other molecules involved in its pathogenesis incl...
Source: Dermatitis - May 3, 2024 Category: Dermatology Authors: Natale Schettini Lucrezia Pacetti Monica Corazza Alessandro Borghi Source Type: research
Natural products as the therapeutic strategies for addiction
Biomed Pharmacother. 2024 May 2;175:116687. doi: 10.1016/j.biopha.2024.116687. Online ahead of print.ABSTRACTWorld Drug Report 2023 concluded that 296 million people abused drugs, 39.5 million became addiction and 494,000 died as a direct or indirect result of addiction. Addiction has become a growing problem that affects individuals, their families, societies, countries and even the world. However, treatment for addiction is only limited to some developed countries because of the high cost, difficult implementation, and time consuming. Therefore, there is an urgent need to develop a low-cost, effective drug for the develo...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - May 3, 2024 Category: Drugs & Pharmacology Authors: Rui Yu De-Lei Kong Cai Liao Ya-Jie Yu Zhen-Wei He Yun Wang Source Type: research
Preventive and restorative alternatives to caries by irradiation: a scoping review
CONCLUSION: Fluoride gel was the most frequently recommended preventive material for preventing radiation caries with supportive clinical evidence. Resin composite and glass ionomer were the most frequently used restorative materials, respectively. However, there is not yet clinical evidence to support the use of resin composite in irradiated teeth.PMID:38702458 | DOI:10.1007/s00520-024-08522-2 (Source: Cancer Control)
Source: Cancer Control - May 3, 2024 Category: Cancer & Oncology Authors: Renata V Monteiro Rodrigo B E Lins Renally B W Lima Kathleen Fischer Grace M De Souza Source Type: research
Overall and geographic pattern of incidence, fatality and mortality of sepsis among hospitalized non-child cancer patients in China: A nationwide cross-sectional study
Sci Bull (Beijing). 2024 Mar 25:S2095-9273(24)00206-8. doi: 10.1016/j.scib.2024.03.050. Online ahead of print.NO ABSTRACTPMID:38702275 | DOI:10.1016/j.scib.2024.03.050 (Source: Cancer Control)
Source: Cancer Control - May 3, 2024 Category: Cancer & Oncology Authors: Bin Lu Yang Xu Na Li Yueyang Zhou Xudong Ma Yan Chen Run Dong Xiang Zhou Min Dai Hongda Chen Li Weng Bin Du China National Critical Care Quality Control Center Group and China Critical Care Clinical Trials Group (CCCCTG) Source Type: research
Association of glucagon-like peptide-1 receptor agonists with risk of cancers-evidence from a drug target Mendelian randomization and clinical trials
CONCLUSIONS: Our study suggests that GLP1RA may decrease the risk of breast cancer and basal cell carcinoma, but increase the risk of colorectal cancer. However, according to the systematic review of RCTs, the incidence of cancer in patients treated with GLP1RA is low. Larger sample sizes of RCTs with long-term follow-up are necessary to establish the incidence of cancers and evaluate the risk-benefit ratios.PMID:38701500 | DOI:10.1097/JS9.0000000000001514 (Source: Cancer Control)
Source: Cancer Control - May 3, 2024 Category: Cancer & Oncology Authors: Yuming Sun Yongjia Liu Yating Dian Furong Zeng Guangtong Deng Shaorong Lei Source Type: research
Minimal Residual Disease Status in Multiple Myeloma 1 Year After Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance Are Associated With Long-Term Overall Survival
CONCLUSION: To our knowledge, this first, prospective US cooperative group, multicenter study demonstrates that MRDneg at Y1 after AutoHCT with lenalidomide maintenance is prognostic for improved 6-year PFS and OS. Serial MRD measurements may direct trials to test how further therapy may improve long-term PFS and OS.PMID:38701390 | DOI:10.1200/JCO.23.00934 (Source: Cancer Control)
Source: Cancer Control - May 3, 2024 Category: Cancer & Oncology Authors: Marcelo C Pasquini Paul K Wallace Brent Logan Manmeet Kaur Joseph D Tario Alan Howard Yali Zhang Claudio Brunstein Yvonne Efebera Nancy Geller Sergio Giralt Parameswaran Hari Mary M Horowitz John Koreth Amrita Krishnan Heather Landau George Somlo Nina Sha Source Type: research
Minimal Residual Disease Status in Multiple Myeloma 1 Year After Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance Are Associated With Long-Term Overall Survival
CONCLUSION: To our knowledge, this first, prospective US cooperative group, multicenter study demonstrates that MRDneg at Y1 after AutoHCT with lenalidomide maintenance is prognostic for improved 6-year PFS and OS. Serial MRD measurements may direct trials to test how further therapy may improve long-term PFS and OS.PMID:38701390 | DOI:10.1200/JCO.23.00934 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - May 3, 2024 Category: Cancer & Oncology Authors: Marcelo C Pasquini Paul K Wallace Brent Logan Manmeet Kaur Joseph D Tario Alan Howard Yali Zhang Claudio Brunstein Yvonne Efebera Nancy Geller Sergio Giralt Parameswaran Hari Mary M Horowitz John Koreth Amrita Krishnan Heather Landau George Somlo Nina Sha Source Type: research
The Missing Trial Variable: A Case Report on Dietary Modification in a Patient with Durable Complete Remission After an Immunotherapy Clinical Trial for Metastatic Bladder Cancer
Altern Ther Health Med. 2024 May 3:AT9333. Online ahead of print.ABSTRACTA patient with metastatic bladder cancer has had an ongoing 9-year complete remission on a clinical trial of immunotherapy with nivolumab and ipimumab, but he also was following an intensive dietary and nutritional supplement regimen. Whether this combination or the immunotherapy alone brought about his good outcome is unknown but could be clarified in future trials by improved data collection about dietary and supplement choices.PMID:38702166 (Source: Alternative Therapies in Health and Medicine)
Source: Alternative Therapies in Health and Medicine - May 3, 2024 Category: Complementary Medicine Authors: Linda L Isaacs Nicholas J Gonzalez Source Type: research
Mesenchymal stem cell-derived exosomes for management of prostate cancer: An updated view
Int Immunopharmacol. 2024 May 2;134:112171. doi: 10.1016/j.intimp.2024.112171. Online ahead of print.ABSTRACTProstate cancer represents the second most prevalent form of cancer found in males, and stands as the fifth primary contributor to cancer-induced mortality on a global scale. Research has shown that transplanted mesenchymal stem cells (MSCs) can migrate by homing to tumor sites in the body. In prostate cancer, researchers have explored the fact that MSC-based therapies (including genetically modified delivery vehicles or vectors) and MSC-derived exosomes are emerging as attractive options to improve the efficacy and...
Source: International Immunopharmacology - May 3, 2024 Category: Allergy & Immunology Authors: Fahimeh Lavi Arab Akram Hoseinzadeh Fatemeh Hafizi Fatemeh Sadat Mohammadi Farid Zeynali Melika Hadad Tehran Amirreza Rostami Source Type: research
Management of patients with diffuse intrinsic pontine glioma in Australia and New Zealand: Australian and New Zealand Children's Haematology/Oncology Group position statement
Med J Aust. 2024 May 3. doi: 10.5694/mja2.52295. Online ahead of print.ABSTRACTINTRODUCTION: The main mission of the Australian and New Zealand Children's Haematology and Oncology Group (ANZCHOG) is to develop and facilitate local access to the world's leading evidence-based clinical trials for all paediatric cancers, including brain tumours, as soon as practically possible. Diffuse intrinsic pontine gliomas (DIPGs) - a subset of a larger group of tumours now termed diffuse midline glioma, H3K27-altered (DMG) - are paediatric brain cancers with less than 10% survival at two years. In the absence of any proven curative ther...
Source: Medical Journal of Australia - May 3, 2024 Category: General Medicine Authors: Santosh Valvi Neevika Manoharan Marion K Mateos Timothy Eg Hassall David S Ziegler Geoffrey B McCowage Matthew D Dun David D Eisenstat Nicholas G Gottardo Jordan R Hansford Source Type: research
Contemporary Management of Pediatric Brainstem Tumors
Adv Tech Stand Neurosurg. 2024;49:231-254. doi: 10.1007/978-3-031-42398-7_11.ABSTRACTBrain tumors are the second most common malignancy in childhood. Around 15-20% of pediatric brain tumors occur in the brainstem. The most common type of brainstem tumor are diffuse tumors in the ventral pons, whereas focal tumors tend to arise from the midbrain, medulla, and dorsal pons. Glioma is the most common pathological entity. Contemporary management consists of surgery, radiotherapy, chemotherapy, and other adjuvant treatment. Surgical options range from biopsy to radical excision. Biopsy can be performed for diagnostic and prognos...
Source: Advances and Technical Standards in Neurosurgery - May 3, 2024 Category: Neurosurgery Authors: Sheng-Che Chou Yu-Ning Chen Hsin-Yi Huang Meng-Fai Kuo Tai-Tong Wong Sung-Hsin Kuo Shih-Hung Yang Source Type: research
Post-marketing safety concerns with elagolix: a disproportionality analysis of the FDA adverse event reporting system
CONCLUSION: Our study provides a comprehensive picture of the safety of elagolix in the post-marketing setting, while also identifying potential new AE signals. These findings emphasize the importance of continued monitoring of the potential risks of elagolix.PMID:38700323 | DOI:10.1080/14740338.2024.2351451 (Source: Expert Opinion on Drug Safety)
Source: Expert Opinion on Drug Safety - May 3, 2024 Category: Drugs & Pharmacology Authors: En Chang Yong-Fang Shi Jin-Feng Liu Wei Wei Source Type: research
Metabolic models predict fotemustine and the combination of eflornithine/rifamycin and adapalene/cannabidiol for the treatment of gliomas
Brief Bioinform. 2024 Mar 27;25(3):bbae199. doi: 10.1093/bib/bbae199.ABSTRACTGliomas are the most common type of malignant brain tumors, with glioblastoma multiforme (GBM) having a median survival of 15 months due to drug resistance and relapse. The treatment of gliomas relies on surgery, radiotherapy and chemotherapy. Only 12 anti-brain tumor chemotherapies (AntiBCs), mostly alkylating agents, have been approved so far. Glioma subtype-specific metabolic models were reconstructed to simulate metabolite exchanges, in silico knockouts and the prediction of drug and drug combinations for all three subtypes. The simulations we...
Source: Briefings in Bioinformatics - May 3, 2024 Category: Bioinformatics Authors: Ali Kishk Maria Pires Pacheco Tony Heurtaux Thomas Sauter Source Type: research
Therapies in preclinical and in early clinical development for the treatment of urinary tract infections: from pathogens to therapies
Expert Opin Investig Drugs. 2024 May 3. doi: 10.1080/13543784.2024.2351509. Online ahead of print.ABSTRACTINTRODUCTION: Urinary tract infections (UTIs) are a prevalent health challenge characterized by the invasion and multiplication of microorganisms in the urinary system. The continuous exploration of novel therapeutic interventions is imperative. Advances in research offer hope for revolutionizing the management of UTIs and improving the overall health outcomes for individuals affected by these infections.AREAS COVERED: This review aimed to provide an overview of existing treatments for UTIs, highlighting their strength...
Source: Expert Opinion on Investigational Drugs - May 3, 2024 Category: Drugs & Pharmacology Authors: Virginia Fuochi Salvatore Furnari Laura Trovato Maddalena Calvo Pio Maria Furneri Source Type: research
